Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger.
Lucio Crino
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Antonio Chella
No relevant relationships to disclose
Fausto Barbieri
No relevant relationships to disclose
Paola Venturino
No relevant relationships to disclose
Antonio Marchetti
No relevant relationships to disclose
Michele Milella
No relevant relationships to disclose
Ariela Brandes
No relevant relationships to disclose
Tommaso De Pas
No relevant relationships to disclose